Combining the results of the two databases, PERK has high expression in brain and CNS cancer, breast cancer, cholangiocarcinoma, liver cancer, lung cancer, and gastric carcinoma and has low expression in lymphoma, sarcoma, colorectal cancer, and thyroid cancer. Here, EIF2AK3 is linked to lung cancer.